Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Rezolute's RZ-402?
RZ-402 is a small molecule commercialized by Rezolute, with a leading Phase II program in Diabetic Macular Edema. According to...
Data Insights
RZ-402 by Rezolute for Diabetic Macular Edema: Likelihood of Approval
RZ-402 is under clinical development by Rezolute and currently in Phase II for Diabetic Macular Edema. According to GlobalData, Phase...